OpenAI in Talks with FDA to Accelerate Drug Approvals Using AI

OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.

• OpenAI has been meeting with the FDA to discuss using AI to speed up the drug approval process.
• The FDA commissioner said the agency recently completed its first AI-assisted scientific review of a product.
• OpenAI has discussed a project called cderGPT with the FDA, which likely relates to using AI for drug evaluation and research.